These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6726088)

  • 1. Genetic polymorphism of apolipoprotein E: a variant form of apolipoprotein E2 distinguished by sodium dodecyl sulfate--polyacrylamide gel electrophoresis.
    Utermann G; Weisgraber KH; Weber W; Mahley RW
    J Lipid Res; 1984 Apr; 25(4):378-82. PubMed ID: 6726088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
    Weisgraber KH; Rall SC; Innerarity TL; Mahley RW; Kuusi T; Ehnholm C
    J Clin Invest; 1984 Apr; 73(4):1024-33. PubMed ID: 6323533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
    J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia.
    Lohse P; Mann WA; Stein EA; Brewer HB
    J Biol Chem; 1991 Jun; 266(16):10479-84. PubMed ID: 1674745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
    Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
    Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological discrimination between the human apolipoprotein E2(Arg158----Cys) and E3 isoforms.
    Gerritse K; de Knijff P; van Ierssel G; Havekes LM; Frants RR; Schellekens MM; Zegers ND; Claassen E; Boersma WJ
    J Lipid Res; 1992 Feb; 33(2):273-80. PubMed ID: 1373757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism in human apolipoprotein E.
    Zannis VI
    Methods Enzymol; 1986; 128():823-51. PubMed ID: 3724530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
    Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
    Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.
    Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB
    J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Frants RR; Havekes LM; Van der Laarse A; Van 't Hooft FM
    Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
    Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
    J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue.
    Smit M; de Knijff P; Frants RR; Klasen EC; Havekes LM
    Clin Genet; 1987 Nov; 32(5):335-41. PubMed ID: 3690877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127.
    Wardell MR; Weisgraber KH; Havekes LM; Rall SC
    J Biol Chem; 1989 Dec; 264(35):21205-10. PubMed ID: 2556398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E Bethesda. Isolation and partial characterization of a variant of human apolipoprotein E isolated from very low density lipoproteins.
    Ghiselli G; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1984 Jul; 794(2):333-9. PubMed ID: 6428460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation.
    Innerarity TL; Weisgraber KH; Arnold KS; Rall SC; Mahley RW
    J Biol Chem; 1984 Jun; 259(11):7261-7. PubMed ID: 6327714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys, Cys112->Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis.
    Ruzicka V; März W; Russ A; Fisher E; Mondorf W; Gross W
    Electrophoresis; 1993 Oct; 14(10):1032-7. PubMed ID: 8125051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of apolipoprotein(AII-E2-AII) complex in human plasma lipoprotein.
    Tozuka M; Hidaka H; Miyachi M; Furihata K; Katsuyama T; Kanai M
    Biochim Biophys Acta; 1992 Nov; 1165(1):61-7. PubMed ID: 1420349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.
    van den Maagdenberg AM; Weng W; de Bruijn IH; de Knijff P; Funke H; Smelt AH; Gevers Leuven JA; van't Hooft FM; Assmann G; Hofker MH
    Am J Hum Genet; 1993 May; 52(5):937-46. PubMed ID: 8488843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.